Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience
Identifieur interne : 002013 ( Istex/Corpus ); précédent : 002012; suivant : 002014Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience
Auteurs : Richard M. Trosch ; Joseph H. Friedman ; Meg C. Lannon ; Rajesh Pahwa ; D. Smith ; Lauren C. Seeberger ; Christopher F. O'Brien ; Peter A. Lewitt ; William C. KollerSource :
- Movement Disorders [ 0885-3185 ] ; 1998-05.
English descriptors
- KwdEn :
Abstract
We conducted a multicentered, retrospective review of clozapine's (CZP) effects on a range of psychiatric, sleep, cognitive, motor, and sensory disorders in Parkinson's disease (PD). Therapeutic outcomes and adverse events were compared with varying prescribing practices at participating sites. The medical records of 172 consecutive PD patients treated with CZP at four movement disorder clinics were reviewed. Low‐dose CZP improved psychiatric symptoms of psychosis, anxiety, depression, hypersexuality, sleep disturbance, and akathisia. Tremor, torticollis, limb dystonia, and pain showed modest rates of improvement. Twenty‐three percent of patients withdrew as a result of adverse events or treatment failure. Inpatient CZP initiation did not improve therapeutic efficacy, or reduce adverse events or the withdrawal rate. Low‐dose CZP in the outpatient setting is generally an effective and well‐tolerated treatment for many of the psychiatric, sleep, motor, and sensory disturbances common to late‐stage PD.
Url:
DOI: 10.1002/mds.870130302
Links to Exploration step
ISTEX:FA580694575C9A074D8D3992108F119B9FC36D73Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience</title><author><name sortKey="Trosch, Richard M" sort="Trosch, Richard M" uniqKey="Trosch R" first="Richard M." last="Trosch">Richard M. Trosch</name><affiliation><mods:affiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</mods:affiliation></affiliation></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation><mods:affiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</mods:affiliation></affiliation></author><author><name sortKey="Lannon, Meg C" sort="Lannon, Meg C" uniqKey="Lannon M" first="Meg C." last="Lannon">Meg C. Lannon</name><affiliation><mods:affiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</mods:affiliation></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Smith, D" sort="Smith, D" uniqKey="Smith D" first="D." last="Smith">D. Smith</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Seeberger, Lauren C" sort="Seeberger, Lauren C" uniqKey="Seeberger L" first="Lauren C." last="Seeberger">Lauren C. Seeberger</name><affiliation><mods:affiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="O Brien, Christopher F" sort="O Brien, Christopher F" uniqKey="O Brien C" first="Christopher F." last="O'Brien">Christopher F. O'Brien</name><affiliation><mods:affiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><affiliation><mods:affiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</mods:affiliation></affiliation></author><author><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FA580694575C9A074D8D3992108F119B9FC36D73</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130302</idno><idno type="url">https://api.istex.fr/document/FA580694575C9A074D8D3992108F119B9FC36D73/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002013</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience</title><author><name sortKey="Trosch, Richard M" sort="Trosch, Richard M" uniqKey="Trosch R" first="Richard M." last="Trosch">Richard M. Trosch</name><affiliation><mods:affiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</mods:affiliation></affiliation></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation><mods:affiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</mods:affiliation></affiliation></author><author><name sortKey="Lannon, Meg C" sort="Lannon, Meg C" uniqKey="Lannon M" first="Meg C." last="Lannon">Meg C. Lannon</name><affiliation><mods:affiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</mods:affiliation></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Smith, D" sort="Smith, D" uniqKey="Smith D" first="D." last="Smith">D. Smith</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Seeberger, Lauren C" sort="Seeberger, Lauren C" uniqKey="Seeberger L" first="Lauren C." last="Seeberger">Lauren C. Seeberger</name><affiliation><mods:affiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="O Brien, Christopher F" sort="O Brien, Christopher F" uniqKey="O Brien C" first="Christopher F." last="O'Brien">Christopher F. O'Brien</name><affiliation><mods:affiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><affiliation><mods:affiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</mods:affiliation></affiliation></author><author><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-05">1998-05</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="377">377</biblScope><biblScope unit="page" to="382">382</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FA580694575C9A074D8D3992108F119B9FC36D73</idno><idno type="DOI">10.1002/mds.870130302</idno><idno type="ArticleID">MDS870130302</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Akathisia</term><term>Clozapine</term><term>Depression</term><term>Pain</term><term>Parkinson's disease</term><term>Psychosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We conducted a multicentered, retrospective review of clozapine's (CZP) effects on a range of psychiatric, sleep, cognitive, motor, and sensory disorders in Parkinson's disease (PD). Therapeutic outcomes and adverse events were compared with varying prescribing practices at participating sites. The medical records of 172 consecutive PD patients treated with CZP at four movement disorder clinics were reviewed. Low‐dose CZP improved psychiatric symptoms of psychosis, anxiety, depression, hypersexuality, sleep disturbance, and akathisia. Tremor, torticollis, limb dystonia, and pain showed modest rates of improvement. Twenty‐three percent of patients withdrew as a result of adverse events or treatment failure. Inpatient CZP initiation did not improve therapeutic efficacy, or reduce adverse events or the withdrawal rate. Low‐dose CZP in the outpatient setting is generally an effective and well‐tolerated treatment for many of the psychiatric, sleep, motor, and sensory disturbances common to late‐stage PD.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Richard M. Trosch MD</name><affiliations><json:string>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</json:string></affiliations></json:item><json:item><name>Joseph H. Friedman MD</name><affiliations><json:string>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</json:string></affiliations></json:item><json:item><name>Meg C. Lannon RN</name><affiliations><json:string>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</json:string></affiliations></json:item><json:item><name>Rajesh Pahwa MD</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</json:string></affiliations></json:item><json:item><name>D. Smith RN</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</json:string></affiliations></json:item><json:item><name>Lauren C. Seeberger MD</name><affiliations><json:string>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</json:string></affiliations></json:item><json:item><name>Christopher F. O'Brien MD</name><affiliations><json:string>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</json:string></affiliations></json:item><json:item><name>Peter A. Lewitt MD</name><affiliations><json:string>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</json:string></affiliations></json:item><json:item><name>William C. Koller MD, PhD</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Clozapine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Psychosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Akathisia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pain</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We conducted a multicentered, retrospective review of clozapine's (CZP) effects on a range of psychiatric, sleep, cognitive, motor, and sensory disorders in Parkinson's disease (PD). Therapeutic outcomes and adverse events were compared with varying prescribing practices at participating sites. The medical records of 172 consecutive PD patients treated with CZP at four movement disorder clinics were reviewed. Low‐dose CZP improved psychiatric symptoms of psychosis, anxiety, depression, hypersexuality, sleep disturbance, and akathisia. Tremor, torticollis, limb dystonia, and pain showed modest rates of improvement. Twenty‐three percent of patients withdrew as a result of adverse events or treatment failure. Inpatient CZP initiation did not improve therapeutic efficacy, or reduce adverse events or the withdrawal rate. Low‐dose CZP in the outpatient setting is generally an effective and well‐tolerated treatment for many of the psychiatric, sleep, motor, and sensory disturbances common to late‐stage PD.</abstract><qualityIndicators><score>5.234</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1014</abstractCharCount><pdfWordCount>3566</pdfWordCount><pdfCharCount>23846</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>139</abstractWordCount></qualityIndicators><title>Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience</title><genre><json:string>Serial article</json:string></genre><host><volume>13</volume><pages><total>6</total><last>382</last><first>377</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1002/mds.870130302</json:string></doi><id>FA580694575C9A074D8D3992108F119B9FC36D73</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/FA580694575C9A074D8D3992108F119B9FC36D73/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/FA580694575C9A074D8D3992108F119B9FC36D73/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/FA580694575C9A074D8D3992108F119B9FC36D73/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1998</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience</title><author><persName><forename type="first">Richard M.</forename><surname>Trosch</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Sinai Clinical Neuroscience Center, 5821 W. Maple Rd., Suite 192, West Bloomfield, MI 48322, U.S.A.===</p></note><affiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</affiliation></author><author><persName><forename type="first">Joseph H.</forename><surname>Friedman</surname><roleName type="degree">MD</roleName></persName><affiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</affiliation></author><author><persName><forename type="first">Meg C.</forename><surname>Lannon</surname><roleName type="degree">RN</roleName></persName><affiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</affiliation></author><author><persName><forename type="first">Rajesh</forename><surname>Pahwa</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation></author><author><persName><forename type="first">D.</forename><surname>Smith</surname><roleName type="degree">RN</roleName></persName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation></author><author><persName><forename type="first">Lauren C.</forename><surname>Seeberger</surname><roleName type="degree">MD</roleName></persName><affiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</affiliation></author><author><persName><forename type="first">Christopher F.</forename><surname>O'Brien</surname><roleName type="degree">MD</roleName></persName><affiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</affiliation></author><author><persName><forename type="first">Peter A.</forename><surname>Lewitt</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</affiliation></author><author><persName><forename type="first">William C.</forename><surname>Koller</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-05"></date><biblScope unit="vol">13</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="377">377</biblScope><biblScope unit="page" to="382">382</biblScope></imprint></monogr><idno type="istex">FA580694575C9A074D8D3992108F119B9FC36D73</idno><idno type="DOI">10.1002/mds.870130302</idno><idno type="ArticleID">MDS870130302</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We conducted a multicentered, retrospective review of clozapine's (CZP) effects on a range of psychiatric, sleep, cognitive, motor, and sensory disorders in Parkinson's disease (PD). Therapeutic outcomes and adverse events were compared with varying prescribing practices at participating sites. The medical records of 172 consecutive PD patients treated with CZP at four movement disorder clinics were reviewed. Low‐dose CZP improved psychiatric symptoms of psychosis, anxiety, depression, hypersexuality, sleep disturbance, and akathisia. Tremor, torticollis, limb dystonia, and pain showed modest rates of improvement. Twenty‐three percent of patients withdrew as a result of adverse events or treatment failure. Inpatient CZP initiation did not improve therapeutic efficacy, or reduce adverse events or the withdrawal rate. Low‐dose CZP in the outpatient setting is generally an effective and well‐tolerated treatment for many of the psychiatric, sleep, motor, and sensory disturbances common to late‐stage PD.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Clozapine</term></item><item><term>Parkinson's disease</term></item><item><term>Psychosis</term></item><item><term>Akathisia</term></item><item><term>Depression</term></item><item><term>Pain</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1997-03-19">Received</change><change when="1998-01-27">Registration</change><change when="1998-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/FA580694575C9A074D8D3992108F119B9FC36D73/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v13:3</doi><numberingGroup><numbering type="journalVolume" number="13">13</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1998-05">May 1998</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="2" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870130302</doi><idGroup><id type="unit" value="MDS870130302"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1998 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1997-03-19"></event><event type="manuscriptRevised" date="1997-10-07"></event><event type="manuscriptAccepted" date="1998-01-27"></event><event type="firstOnline" date="2004-11-04"></event><event type="publishedOnlineFinalForm" date="2004-11-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.3.2 mode:FullText" date="2014-06-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.3.2 mode:FullText" date="2014-06-23"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">377</numbering><numbering type="pageLast">382</numbering></numberingGroup><correspondenceTo>Sinai Clinical Neuroscience Center, 5821 W. Maple Rd., Suite 192, West Bloomfield, MI 48322, U.S.A.===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870130302.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="37"></count></countGroup><titleGroup><title type="main" xml:lang="en">Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience</title><title type="short" xml:lang="en">CLOZAPINE USE IN PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Richard M.</givenNames><familyName>Trosch</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Joseph H.</givenNames><familyName>Friedman</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Meg C.</givenNames><familyName>Lannon</familyName><degrees>RN</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Rajesh</givenNames><familyName>Pahwa</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>D.</givenNames><familyName>Smith</familyName><degrees>RN</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Lauren C.</givenNames><familyName>Seeberger</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Christopher F.</givenNames><familyName>O'Brien</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Peter A.</givenNames><familyName>Lewitt</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af3"><personName><givenNames>William C.</givenNames><familyName>Koller</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Clozapine</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">Psychosis</keyword><keyword xml:id="kwd4">Akathisia</keyword><keyword xml:id="kwd5">Depression</keyword><keyword xml:id="kwd6">Pain</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We conducted a multicentered, retrospective review of clozapine's (CZP) effects on a range of psychiatric, sleep, cognitive, motor, and sensory disorders in Parkinson's disease (PD). Therapeutic outcomes and adverse events were compared with varying prescribing practices at participating sites. The medical records of 172 consecutive PD patients treated with CZP at four movement disorder clinics were reviewed. Low‐dose CZP improved psychiatric symptoms of psychosis, anxiety, depression, hypersexuality, sleep disturbance, and akathisia. Tremor, torticollis, limb dystonia, and pain showed modest rates of improvement. Twenty‐three percent of patients withdrew as a result of adverse events or treatment failure. Inpatient CZP initiation did not improve therapeutic efficacy, or reduce adverse events or the withdrawal rate. Low‐dose CZP in the outpatient setting is generally an effective and well‐tolerated treatment for many of the psychiatric, sleep, motor, and sensory disturbances common to late‐stage PD.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>CLOZAPINE USE IN PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience</title></titleInfo><name type="personal"><namePart type="given">Richard M.</namePart><namePart type="family">Trosch</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</affiliation><description>Correspondence: Sinai Clinical Neuroscience Center, 5821 W. Maple Rd., Suite 192, West Bloomfield, MI 48322, U.S.A.===</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph H.</namePart><namePart type="family">Friedman</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Meg C.</namePart><namePart type="family">Lannon</namePart><namePart type="termsOfAddress">RN</namePart><affiliation>Division of Neurology, Roger Williams Medical Center, Providence, Rhode Island</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rajesh</namePart><namePart type="family">Pahwa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Smith</namePart><namePart type="termsOfAddress">RN</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lauren C.</namePart><namePart type="family">Seeberger</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher F.</namePart><namePart type="family">O'Brien</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Colorado Neurological Institute, Denver, Colorado, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter A.</namePart><namePart type="family">Lewitt</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William C.</namePart><namePart type="family">Koller</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1998-05</dateIssued><dateCaptured encoding="w3cdtf">1997-03-19</dateCaptured><dateValid encoding="w3cdtf">1998-01-27</dateValid><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">37</extent></physicalDescription><abstract lang="en">We conducted a multicentered, retrospective review of clozapine's (CZP) effects on a range of psychiatric, sleep, cognitive, motor, and sensory disorders in Parkinson's disease (PD). Therapeutic outcomes and adverse events were compared with varying prescribing practices at participating sites. The medical records of 172 consecutive PD patients treated with CZP at four movement disorder clinics were reviewed. Low‐dose CZP improved psychiatric symptoms of psychosis, anxiety, depression, hypersexuality, sleep disturbance, and akathisia. Tremor, torticollis, limb dystonia, and pain showed modest rates of improvement. Twenty‐three percent of patients withdrew as a result of adverse events or treatment failure. Inpatient CZP initiation did not improve therapeutic efficacy, or reduce adverse events or the withdrawal rate. Low‐dose CZP in the outpatient setting is generally an effective and well‐tolerated treatment for many of the psychiatric, sleep, motor, and sensory disturbances common to late‐stage PD.</abstract><subject lang="en"><genre>Keywords</genre><topic>Clozapine</topic><topic>Parkinson's disease</topic><topic>Psychosis</topic><topic>Akathisia</topic><topic>Depression</topic><topic>Pain</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>377</start><end>382</end><total>6</total></extent></part></relatedItem><identifier type="istex">FA580694575C9A074D8D3992108F119B9FC36D73</identifier><identifier type="DOI">10.1002/mds.870130302</identifier><identifier type="ArticleID">MDS870130302</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1998 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002013 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002013 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:FA580694575C9A074D8D3992108F119B9FC36D73
|texte= Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience
}}
| This area was generated with Dilib version V0.6.23. |  |